DEVELOPMENT OF A COMMERCIAL POINT-OF-CARE DEVICE CAPABLE OF ELECTRONICALLY SENSI

该提案的长期目标是开发能够电子感测癌症患者外周血中的单个循环肿瘤细胞（CTC）的商业即时检测装置。viratrode是一个纳米技术平台，代表了重大的技术进步。它包含一个基于电极的生物传感器，可以提供一种廉价的格式，用于高灵敏度的即时诊断。viratrode包含一个由丝状噬菌体颗粒组成的生物亲和层，其中每个颗粒可以展示特定癌细胞表面标记的多个配体。这种形式最大化特异性和亲和力，同时最小化生物污垢。viratrode包含一个灵敏的区域检测器，能够检测个位数或更低nM浓度的生物标志物。我们的技术目标集中于构建用于检测前列腺癌CTC的病毒载体。我们的目标标志物包括PSA、PSMA、PSCA和V3整合素。将对viratrodes进行优化，用于识别和实时电检测在生物相关流体基质中表达靶标记的前列腺癌细胞。

The long term goal of this proposal is the development of a commercial point-of-care device capable of electronically sensing single circulating tumor cells (CTC) in the peripheral blood of a cancer patient. The viratrode is a nanotechnology platform that represents a significant technological advance. It contains an electrode-based biosensor and can provide an inexpensive format for point-of-care diagnosis with high sensitivity. The viratrode incorporates a bioaffinity layer consisting of a ¿kelp forest¿ of filamentous phage particles, in which each particle can display multiple ligands to a particular cancer cell surface marker. This format maximizes specificity and affinity, while minimizing biofouling. The viratrode incorporates a sensitive area detector capable of detecting single digit or lower nM concentrations of biomarkers. Our Technical Objectives focus on constructing viratrodes for detecting prostate cancer CTC¿s. Our target markers include PSA, PSMA, PSCA, and vβ3 intergrins. The viratrodes will be optimized for the recognition and real-time electrical detection of prostate cancer cells that express the target markers in a biologically relevant fluid matrix.